

OIE Reference Laboratory Reports Activities

Activities in 2019

This report has been submitted : 2020-01-15 16:56:22

Name of disease (or topic) for which you are a designated OIE Reference Laboratory:	Myxomatosis
Address of laboratory:	Via Antonio Bianchi 9 25124 Brescia ITALY
Tel.:	+39-030 22.90.617
Fax:	+39-030 22.90.559
E-mail address:	antonio.lavazza@izsler.it
Website:	https://www.izsler.it/izs_home_page/servizi/00003931_OIE_Reference_Laboratory_for_Myxomatosis_of_Rabbits.html
Name (including Title) of Head of Laboratory (Responsible Official):	Dr. Giorgio Varisco, Acting General Director
Name (including Title and Position) of OIE Reference Expert:	Dr. Antonio Lavazza, Head of Virology Unit
Which of the following defines your laboratory? Check all that apply:	Governmental

ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of test performed last year	
		Nationally	Internationally
Indirect diagnostic tests		Nationally	Internationally
c-ELISA	yes	89	1
Direct diagnostic tests		Nationally	Internationally
Negative satining EM	yes	22	0
Cell Culture isoaltion	yes	0	0
Immunoperoxidase	yes	0	0
PCR	yes	26	0
Immunofluorescence	yes	0	0

ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards. To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

Yes

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient OIE Member Countries	Region of recipients
Serological kit	C-ELISA	produced	0	2 kits	1	<input type="checkbox"/> Africa <input type="checkbox"/> Americ as <input type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East
Monoclonal Antibodies	Immunohistochemistry	produced		1 ml	1	<input type="checkbox"/> Africa <input type="checkbox"/> Americ as <input type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

No

ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific

and technical advice on disease control measures to OIE Member Countries

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

Yes

Name of OIE Member Country seeking assistance	Date (month)	No. samples received for provision of diagnostic support	No. samples received for provision of confirmatory diagnoses
SOUTH AFRICA	July	1	0

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

Yes

Name of the OIE Member Country receiving a technical consultancy	Purpose	How the advice was provided
QATAR	Information on testing rabbit sera for live rabbit importation in Sri Lanka	Message by email
JAPAN	Myxomatosis testing of for trade of rabbit products	Visit and talk on site
SOUTH AFRICA	Interpretation of results from serological testing rabbits	Message by email
SPAIN	Serological testing of hares sera for anti-myxomatosis antibodies	Message by email

ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

No

ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases

11. Did your Laboratory collect epizootiological data relevant to international disease control?

No

If the answer is no, please provide a brief explanation of the situation:

The cases of myxomatosis worldwide are extremely rare. Indeed, the disease is more frequently observed in wild animals for which the epizootological data are very poor.

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

No

If the answer is no, please provide a brief explanation of the situation:

There are no available data received from member countries. Myxomatosis is an "old" disease and its occurrence is only sporadically reported, mainly in wild animals. Its incidence in farmed rabbits is low and nowadays has a low economic impact in endemic areas (e.g. South Europe) being the infection well controlled by vaccination. Other than the recent (2018) occurrence of new Myxomatosis strains affecting hares in Iberian Peninsula, in the last ten years the disease has been reported only in UK (2016 and 2018), Mexico (2015) and Brazil (2013).

**13. What method of dissemination of information is most often used by your laboratory?
(Indicate in the appropriate box the number by category)**

a) Articles published in peer-reviewed journals: 0

b) International conferences: 0

c) National conferences: 0

d) Other:

(Provide website address or link to appropriate information) 1

http://www.izsler.it/izs_home_page/servizi/00003935_Publications.html

ToR 7: To provide scientific and technical training for personnel from OIE Member Countries

To recommend the prescribed and alternative tests or vaccines as OIE Standards

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

Yes

a) Technical visits: 1

b) Seminars: 1

c) Hands-on training courses: 0

d) Internships (>1 month): 0

Type of technical training provided (a, b, c or d)	Country of origin of the expert(s) provided with training	No. participants from the corresponding country
a	POLAND	2
b	FRANCE	2

ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned

15. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)
UNI CEI ENISO/IEC 17025	CERTIFICATO DI ACCREDITAMENTOnew.pdf

16. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
PCR	ILAC MRA - ACCREDIA
Serological Competitive MAb ELISA (c-ELISA)	ILAC MRA - ACCREDIA
Immunohistochemistry	ILAC MRA - ACCREDIA
EM negative staining methods	ILAC MRA - ACCREDIA

17. Does your laboratory maintain a “biorisk management system” for the pathogen and the disease concerned?

Yes

(See *Manual of Diagnostic Tests and Vaccines for Terrestrial Animals*, Chapter 1.1.4)

ToR 9: To organise and participate in scientific meetings on behalf of the OIE

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

Yes

Title of event	Date (mm/yy)	Location	Role (speaker, presenting poster, short communications)	Title of the work presented
87° OIE GENERAL SESSION	May 2019	Paris	Member of the Italian delegation	-

ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

Not applicable (Only OIE Reference Lab. designated for disease)

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

Not applicable (Only OIE Reference Lab. designated for disease)

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Not applicable (Only OIE Reference Lab. designated for disease)

ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

No

Note: See *Interlaboratory test comparisons in: Laboratory Proficiency Testing* at: <http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing> see point 1.3

ToR 12: To place expert consultants at the disposal of the OIE

24. Did your laboratory place expert consultants at the disposal of the OIE?

Yes

Kind of consultancy	Location	Subject (facultative)
Review of OIE Standards	-	We have been asked to update of the Chapter on Myxomatosis of the OIE Terrestrial Manual. This will be completed within 2020

25. Additional comments regarding your report:

Myxomatosis is an "old" disease and its occurrence is only sporadically reported, mainly in wild animals. Therefore the available epizootological data are poor and the request for analysis and scientific advice are equally rare.

Nevertheless we are going to update and review the chapter of the OIE Terrestrial Manual including few new data on the disease.

In addition, we are still trying to increase the number of formal and informal contacts with laboratories from member countries for supplying PCR methods and reference samples, and for performing diagnostic tests.